Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: New tools to study antigen presentation and TCR-peptide-MHC interactions

Journal of Molecular Recognition

Volumn 16, Issue 5, 2003, Pages 324-332

  Cohen, Cyril J ^a   Denkberg, Galit ^a   Lev, Avital ^a   Epel, Malka ^a   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

MHC peptide; Phage display; Recombinant antibodies; T cell receptor

Indexed keywords

ANIMALS; ANTIBODIES; ANTIGEN PRESENTATION; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141872929     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.640     Document Type: Conference Paper

References (48)

1. Aharoni R, Teitelbaum D, Arnon R, Puri J. 1991. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-la complex. Nature 351: 147-150.
2. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. [Published erratum appears in Science 1998; 280(5371): 1821.]
3. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. 1996. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells. Proc. Natl Acad. Sci. USA 93: 1820-1824.
4. Boon T, van der BP. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
5. Bouvier M, Wiley DC. 1994. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 265: 398-402.
6. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. 2000. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl Acad. Sci. USA 97: 7969-7974.
7. Christinck ER, Luscher MA, Barber BH, Williams DB. 1991. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352: 67-70.
8. Cloutier SM, Couty S, Terskikh A, Marguerat L, Crivelli V, Pugnieres M, Mani JC, Leisinger HJ, Mach JP, Deperthes D. 2000. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol. Immunol. 37: 1067-1077.
9. Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. 2002. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of . Cancer Res. 62: 5835-5844.
10. Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. 2003. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J. Immunol. (in press).
11. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA. 1994. Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity 1: 121-130.
12. Collins EJ, Booth BL, Jr, Cerundolo V. 1999. Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition. J. Immunol. 162: 331-337.
13. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER. 1997. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 6: 727-738.
14. Day PM, Yewdell JW, Porgador A, Germain RN, Bennink JR. 1997. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc. Natl Acad. Sci. USA 94: 8064-8069.
15. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruine AP, Arends JW, Hoogenboom HR. 1999. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274: 18218-18230.
16. Denkberg G, Cohen CJ, Segal D, Kirkin AF, Reiter Y. 2000. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 30: 3522-3532.
17. Denkberg G, Cohen CJ, Reiter Y. 2001. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR. J. Immunol. 167: 270-276.
18. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. 2002a. Direct visualization of distinct T-cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T-cell receptor-like specificity. Proc. Natl Acad. Sci. USA 99: 9421-9426.
19. Denkberg G, Klechevsky E, Reiter Y. 2002b. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J. Immunol. 169: 4399-4407.
20. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. 1989. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 342: 692-696.
21. Germain RN, Margulies DH. 1993. The biochemistry and cell biology of antigen processing and presentation. A. Rev. Immunol. 11: 403-450.
22. Guo HC, Madden DR, Silver ML, Jardetzky TS, Gorga JC, Strominger JL, Wiley DC. 1993. Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201,and HLA-B*2705. Proc. Natl Acad. Sci. USA 90: 8053-8057.
23. Khan AR, Baker BM, Ghosh P, Biddison WE, Wiley DC. 2000. The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J. Immunol. 164: 6398-6405.
24. Klein J, Sato A. 2000. The HLA system. First of two parts. New Engl. J. Med. 343: 702-709.
25. Krogsgaard M, Wucherpfennig KW, Canella B, Hansen BE, Svejgaard A, Pyrdol J, Ditzel H, Raine C, Engberg J, Fugger L. 2000. Visualization of myelin basic protein (MBP) T-cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191: 1395-1412.
26. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. 1999. Characterization of circulating T-cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5: 677-685.
27. Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y. 2002. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 62: 3184-3194.
28. Matsumura M, Fremont DH, Peterson PA, Wilson IA. 1992. Emerging principles for the recognition of peptide antigens by MHC class I molecules [See comments.] Science 257: 927-934.
29. Murphy DB, Lo D, Rath S, Brinster RL, Flavell RA, Slanetz A, Janeway CA, Jr. 1989. A novel MHC class II epitope expressed in thymic medulla but not cortex. Nature 338: 765-768.
30. Niedermann G. 2002. Immunological functions of the proteasome. Curr. Top. Microbiol. Immunol. 268: 91-136.
31. Polakova K, Plaksin D, Chung DH, Belyakov IM, Berzofsky JA, Margulies DH. 2000. Antibodies directed against the MHC-1 molecule H-2D(d) complexed with an antigenic peptide: similarities to a T-cell receptor with the same specificity. [In Process Citation.] J. Immunol. 165: 5703-5712.
32. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
33. Rammensee HG, Falk K, Rotzschke O. 1993. Peptides naturally presented by MHC class I molecules. A. Rev. Immunol. 11: 213-244.
34. Reiter Y, Di Carlo A, Fugger L, Engberg J, Pastan I. 1997. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T-cell receptor-like specificity. Proc. Natl Acad. Sci. USA 94: 4631-4636.
35. Renkvist N, Castelli C, Robbins PF, Parmiani G. 2001. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother. 50: 3-15.
36. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177: 265-272.
37. Rognan D, Stryhn A, Fugger L, Lyngbaek S, Engberg J, Andersen PS, Buus S. 2000. Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two alpha beta T-cell receptors. J. Comput. Aided Mol. Des. 14: 53-69.
38. Rosenberg SA. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
39. Rudolph MG, Wilson IA. 2002. The specificity of TCR/pMHC interaction. Curr. Opin. Immunol. 14: 52-65.
40. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74: 929-937.
41. Seliger B, Maeurer MJ, Ferrone S. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21:455-464.
42. Sharma AK, Kuhns JJ, Yan S, Friedline RH, Long B, Tisch R, Collins EJ. 2001. Class I major histocompatibility complex anchor substitutions alter the conformation of T-cell receptor contacts. J. Biol. Chem. 276: 21443-21449.
43. Stryhn A, Andersen PS, Pedersen LO, Svejgaard A, Holm A, Thorpe CJ, Fugger L, Buus S, Engberg J. 1996. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex. Proc. Natl Acad. Sci. USA 93: 10338-10342.
44. Wulfing C, Pluckthun A. 1994. Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts. J. Mol. Biol. 242: 655-669.
45. Yewdell JW. 2001. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol. 11: 294-297.
46. Yewdell JW, Bennink JR. 2001. Cut and trim: generating MHC class I peptide ligands. Curr. Opin. Immunol. 13: 13-18.
47. Zhong G, Reis e Sousa, Germain RN. 1997a. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J. Exp. Med. 186: 673-682.
48. Zhong G, Reis e Sousa, Germain RN. 1997b. Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc. Natl Acad. Sci. USA 94: 13856-13861.